Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers.
Modest differences in the clearance of the 5HT3 antagonist, ondansetron, among different age groups were detected in two groups of healthy elderly volunteers, one group aged 61 to 74 years ("elderly") and the other 75 to 82 ("aged") years, in addition to young healthy subjects. Both a single 0.15 mg/kg intravenous dose and a single 8 mg oral dose were administered according to a randomized crossover design with a minimum 3-day washout period between treatments. Mean plasma clearance decreased (young, 0.349 L/hr/kg; elderly, 0.279 L/hr/kg; aged, 0.214 L/hr/kg; p less than 0.05) with increasing age. Volume of distribution at steady state was unaffected by age (young, 1.81 L/kg; elderly, 1.94 L/kg; aged, 1.71 L/kg), resulting in increases in mean plasma half-life (young, 3.4 hours; elderly, 4.5 hours; aged, 5.4 hours) and mean absolute bioavailability (young, 57%; elderly, 61%; aged, 69%) with increasing age. Female subjects cleared ondansetron more slowly than males (p less than 0.05), resulting in higher absolute bioavailability. Ondansetron was well tolerated by all age groups with no increase in the number of adverse events observed in older volunteers.
Pritchard
J F
JF
Department of Clinical Pharmacokinetics, Glaxo Inc. Research Institute, Research Triangle Park, NC 27709.
Bryson
J C
JC
Kernodle
A E
AE
Benedetti
T L
TL
Powell
J R
JR
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000493:pharmacokinetics* / Q000592:standards; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D017294:Ondansetron; D012702:Serotonin Antagonists; D012727:Sex Characteristics
D007093:Imidazoles; D012702:Serotonin Antagonists; D017294:Ondansetron